Miami, FL (PRWEB) January 16, 2012
Nutri-Med Logic Corp: Over the last 40 years, many studies have reported the benefits of R-Alpha Lipoic in Diabetes. A search of all published studies in PubMed reveals that this recently published study, in the European Journal of Nutrition, is the first to report a reduced level of ALT (Alanine Aminotransferase), an indicator of liver injury, as well as reduced levels of AST (aspartate aminotransferases ), also a marker of liver health but also found in heart (cardiac muscle), kidneys, brain and red blood cells, in the study of diabetes and Alpha Lipoic.
According to the American Diabetes Association, chronic or even mild elevations of ALT and AST is frequently found in type 2 diabetic patients and/or generally conveys an underlying insulin resistance. The concentration of intracellular hepatic (liver) enzymes that have leaked into the circulation could be a predicator of liver injury. (1)
High AST levels, also, generally manifest liver damage or muscle damage or both, which arises from metabolic disorders, as well.
The reduced form of R-Alpha Lipoic Acid is a vital and biological co-enzymes, produced by the cells in the metabolism of glucose (production of energy). R-Alpha Lipoic is found in variety of food but its concentration does not increase significantly form food but only from its dietary supplementation.
In Germany, R-Alpha Lipoic (also known as R-Lipoic Acid) has been used, for more four decades, as a co-therapy in the treatment of Diabetic Poly-Neuropathy. As the matter of fact, a newly published report on clinical trials of last 10 years, relating to the benefits of R-Alpha Lipoic and the various claims made about it, found Diabetic Polyneuropathy receiving the clearest benefit from R-Alpha Lipoic. (2)
In Japan, Alpha Lipoic Acid was previously sold only as a medicine. In June 2004, the Ministry of Health, Labor, and Welfare of Japan reclassified Alpha Lipoic Acid as a nutrient.
Interestingly, the first human clinical studies in the United States was carried out in late 70's by Dr. Fredrick C. Bartter and Dr. Burton M. Berkson, two associates of the National Institutes of Health for the treatment of chronic liver damage, with about 95% improvement (75 out of 79).
Dr. Burkson, subsequently, received a special license from FDA for the intravenous application of Alpha Lipoic Acid and has been the FDA principal Investigator for intravenous application of Alpha Lipoic Acid for the last 23 years.
In 1996, Professor Lester Packer a senior anti-oxidant researcher and scientist at the University of California (Berkley) declared R-Alpha Lipoic as a universal antioxidant, since it dissolves in water and fat, thus, capable of reaching the entire body.
In the United States, R-Alpha Lipoic Acid is dietary supplement and its application as nutrient should not be confused with its IV application.
In conclusion, Nutri-Med Logic Corp agrees with this recent study and adds that R-Alpha Lipoic is also an effective dietary supplement for Diabetes Neuropathy. Additionally, when taking the results of this study, improvement of ALT and AST in liver of diabetic animals, together with the reversal of liver disease, by Dr. Burkson, R-Alpha Lipoic may have extended its benefits beyond its sole association with diabetes and might offer benefits as a general liver dietary supplement, as well.
Nutri-Med Logic Corp. is a producer of dietary supplements, including a Pharmaceutical Grade R-Alpha Lipoic Acid, the dietary supplement of choice for the Diabetics, in Germany for more than 40 years.
Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy and the recommended dietarty supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for about 50 years.
Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.
It must be noted that the studies, sources or statements above or below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.
1. Clinical Diabetes July 2005 vol. 23 no. 3 115-119
2. Front Pharmacol. 2011;2:69. Epub 2011 Nov 17.